Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.49 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.49 |
| ▸ | FBP1 | P09467 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21835395 | 0.89 | EGFR (0.55) | EGFRRIPK2EPHB2FBP1ABCG2 | |
| SCHEMBL21835522 | 0.89 | ABCG2 (0.56) | EGFRRIPK2EPHB2FBP1ABCG2 | |
| SCHEMBL21835242 | 0.88 | ERBB2 (0.58) | EGFRFBP1ABCG2ERBB2 | |
| SCHEMBL15391257 | 0.87 | EGFR (0.58) | EGFRRIPK2EPHB2FBP1ABCG2 | |
| SCHEMBL31472871 | 0.87 | EGFR (0.58) | EGFRRIPK2EPHB2FBP1ABCG2 | |
| SCHEMBL21835413 | 0.86 | EGFR (0.50) | EGFRRIPK2EPHB2FBP1ABCG2 | |
| SCHEMBL29718908 | 0.84 | ERBB2 (0.59) | EGFRERBB2 | |
| SCHEMBL22983917 | 0.84 | ERBB2 (0.59) | EGFRERBB2 | |
| SCHEMBL26321 | 0.82 | EGFR (0.64) | EGFRFBP1ABCG2ERBB2 | |
| SCHEMBL21835506 | 0.81 | EGFR (0.49) | EGFRRIPK2EPHB2ABCG2ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| CN-113382986-A | Tyrosine kinase inhibitor compositions, methods of making and methods of using the same | 黑钻治疗公司 | 2021-09-10 | — | — | CN | disclosed |
| US-11034672-B1 | Tyrosine kinase inhibitor compositions, methods of making and methods of use | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210163447-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. | 2021-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034672-B1 | Tyrosine kinase inhibitor compositions, methods of making and methods of use | ERBB2, ERBB3, EGFR | EGFR 3/4885RIPK2 760/4885EPHB2 205/4885 |
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | ERBB2, ERBB3, EGFR | EGFR 3/4885RIPK2 760/4885EPHB2 205/4885 |
| US-20210163447-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | ERBB2, ERBB3, EGFR | EGFR 3/4885RIPK2 760/4885EPHB2 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.